PlantForm Granted European Patent
GUELPH, Ont., Canada, May 2, 2018—PlantForm Corporation has been granted a patent by the European Patent Office – Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments – under patent no. 2355849.
The patent pertains to technology that improves the therapeutic efficacy and utility of antibody fragments by linking them to other antibodies, so they remain active in the body for a longer period of time.
“This patent is further evidence of PlantForm innovation as we continue to advance our proprietary, plant-based vivoXPRESS® technology system to develop important antibody and protein drugs for a wide range of diseases and life-threatening conditions,” said Doug Cossar, PlantForm’s Vice-President, Research.
PlantForm licenses this technology from the University of Guelph, where it was invented by Dr. J. Christopher Hall, the company’s Chief Scientific Officer.
“It’s gratifying when a patent is issued for one of the University’s inventions, particularly so when it’s associated with a U of G startup company that is creating jobs in Ontario,” said Steve De Brabandere, Associate Director of the University of Guelph’s Research Innovation Office.
PlantForm has an expanding portfolio of patents in six families to protect both the core platform technology and products in development.
About PlantForm Corporation (www.plantformcorp.com)
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty antibody and protein drugs using the company’s proprietary vivoXPRESS® platform
. The plant-based vivo
system makes it easier, faster and less expensive to produce approved biologic drugs for novel indications and new markets. The company’s pipeline includes trastuzumab for a novel indication in nerve regeneration, a biosimilar version of Lucentis® and other niche indication drugs. Learn more.
For more information, please contact:
Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook: